Altimmune (ALT) Restructuring Costs (2015)

Altimmune (ALT) posted quarterly Restructuring Costs of $26886.0 for Q4 2015, down 93.64% quarter-over-quarter from $422482.0 in Q3 2015.

Altimmune (ALT) Restructuring Costs (2015) Analysis & Trends

Altimmune (ALT) has reported Restructuring Costs for 1 consecutive years, with $26886.0 the latest figure, recorded in Q4 2015.

In Q4 2015, Restructuring Costs changed N/A year-over-year to $26886.0; the TTM figure through Sep 2016 stood at $26886.0 (changed N/A YoY), while the FY2015 annual figure was $2.5 million, changed N/A from the prior year.
Restructuring Costs declined to $26886.0 in Q4 2015 per ALT's latest filing, from $422482.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $2.1 million in Q1 2015 and bottomed at $26886.0 in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Altimmune	571.75 Mn	571.75 Mn	-

Download Data